Using a biosimilar can produce substantial cost savings in patients who are receiving infliximab therapy for inflammatory diseases like rheumatoid arthritis (RA), but dose escalations, which are frequent for those who use infliximab, can increase the cost of therapy, even with a biosimilar.
Using a biosimilar can produce substantial cost savings in patients who are receiving infliximab therapy for inflammatory diseases like rheumatoid arthritis (RA), but dose escalations, which are frequent for those who use infliximab, can increase the cost of therapy, even with a biosimilar.
Recently, in a paper appearing this month in Arthritis Research and Therapy, investigators studied the frequency of dose escalation with biosimilar infliximab versus using an alternative agent—like golimumab—that is subject to fewer dose escalations.
In the study, the authors assembled 2 cohorts of Medicare beneficiaries with RA who were starting treatment with either infliximab (n = 5147) or intravenous golimumab (n = 2843). They used CMS fee-for-service Medicare data from 2012 to 2016 to compare dose escalation (defined as a dose increase of 100 mg or more for infliximab or 50 mg or more for golimumab, or increased frequency of dosing), persistence, and the cost to Medicare.
A hypothetical modeling scenario was used to compare dose-escalated infliximab versus golimumab using Medicare-approved amounts in the first quarter of 2016 to evaluate the extent to which dose escalation would be needed before it offset higher Medicare-approved payment a mounts for golimumab, and the model took into account potential discounts for biosimilar infliximab.
They found that dose escalation occurred in 49% of patients receiving infliximab, versus just 5% of those receiving golimumab. Physician ownership of infusion centers was associated with an increased likelihood that infliximab doses would be increased (odds ratio, 1.25; 95% CI, 1.09-1.44).
The mean costs paid by Medicare over the initial 18 months of treatment were higher for golimumab ($28,146, standard deviation [SD]; $16,030) than for infliximab ($21,216; SD, $15,819). Among patients who persisted with treatment through 18 months, least square mean costs were $43,940 for golimumab and $34,671 for infliximab.
In the modeling scenario used to evaluate the level of dosing that would be required to offset higher costs of golimumab use, all dosing frequencies of infliximab at doses of either 3 mg/kg or 5 mg/kg yielded lower annual costs than golimumab. At 10 mg/kg every 6 weeks, infliximab became more costly than golimumab unless discounts of 30% of higher were applied. At 10 mg/kg every 4 weeks, discounts of 50% of greater would be necessary. Given the 21% average sales price discount of the biosimilar Inflectra in 2019, even a dose of infliximab at 8 mg/kg every 6 weeks would be cost-neutral or cost-saving versus golimumab.
The authors conclude that, “costs associated with dose escalating infliximab to 10 mg/kg every 4 or 6 weeks are substantial and likely offset even appreciable dose savings associated with biosimilars,” and, in patients who require such escalations, using an alternative therapy is likely to be less expensive while achieving similar outcomes. For all other lower doses, costs associated with dose escalation are likely to be offset by biosimilar savings.
Reference
Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis [published online December 12, 2019]. Arthritis Res Ther. doi: 10.1186/s13075-019-2022-8.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.